Vimarsana
Biggest News Aggregation in the World

Page 40 - Bivalent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bivalent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bivalent Today - Breaking & Trending Today

DGAP-News: EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union - Vimarsana News

DGAP-News: EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union

Published: September 1, 2022

DGAP-News: Moderna, Inc. / Key word(s): Miscellaneous EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union 01.09.2022 / 15:35 CET/CEST The issuer is solely re...

Source: boersennews.de
Related Topics:
United StatesUnited KingdomLavina TalukdarLuke Mircea WillatsEuropean CommissionDistribution ServicesExchange CommissionEuropean UnionCorporate CommunicationsEuropean Medicines AgencyModerna IncCommittee For Medicinal Products Human UseMedicinal ProductsHuman UseOmicron Targeting Bivalent BoosterChief ExecutivePrivate Securities Litigation Reform ActAnnual ReportQuarterly ReportVice PresidentCorporate NewsRegulatory AnnouncementsModerna SMicron TargetingEt Cest
BioNTech SE: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union - Vimarsana News

BioNTech SE: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Published: September 1, 2022

CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccineThe Omicron BA.1-adapted bivalent COVID-19 vaccine combines

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomSylke MaasAlbert BourlaUgur SahinFosun PharmaInternational Coalition Of Medicines Regulatory AuthoritiesEuropean UnionCommittee For Medicinal Products Human UsePfizer Inc NasdaqWorld Health OrganizationDrug AdministrationEuropean CommissionExchange CommissionRoche GroupEuropean Medicines AgencyMedicinal ProductsHuman UseChief Executive OfficerInternational CoalitionMedicines Regulatory AuthoritiesMarketing Authorization HolderProduct CharacteristicsPackage LeafletBreakthroughs That Change Patient
Moderna, Inc.: Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older - Vimarsana News

Moderna, Inc.: Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older

Published: August 31, 2022

Moderna's Bivalent Booster Shots to be Available Nationwide In Coming DaysmRNA-1273.222 Targets BA.4/.5 Strains of Omicron VariantCAMBRIDGE, MA / ACCESSWIRE / August 31, 2022 / Moderna, Inc. (NASDAQ:MRNA)

Source: finanznachrichten.de
Related Topics:
United KingdomUnited StatesElise MeyerLavina TalukdarExchange CommissionCorporate CommunicationsRadiological Nuclear DefenseModerna IncDrug AdministrationArmy ContractingBivalent Booster ShotsAvailable Nationwide In ComingChief Executive OfficerDefense Joint Program Executive OfficeArmy Contracting CommandEmergency Use AuthorizationCoronavirus DiseaseVaccine Adverse Event Reporting SystemVaccine Fact SheetsHealthcare Providers Administering VaccineVaccine ProvidersFull Prescribing InformationPrivate Securities Litigation Reform ActAnnual ReportQuarterly Report
BioNTech SE: Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older - Vimarsana News

BioNTech SE: Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Published: August 31, 2022

Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccinesPfizer-BioNTech Omicron BA.4/BA.5 bivalent vaccine combines 15-µg of mRNA encoding the wild-type

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomSylke MaasAlbert BourlaUgur SahinFosun PharmaCenters For DiseasePfizer Inc NasdaqDrug AdministrationAdvisory Committee On Immunization PracticesExchange CommissionPfizer IncEuropean UnionEuropean Medicines AgencyRoche GroupEmergency Use AuthorizationChief Executive OfficerDisease ControlAdvisory CommitteeImmunization PracticesBiologics License ApplicationMarketing Authorization HolderCoronavirus DiseaseFact SheetsPrescribing Information
Pfizer Inc.: Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older - Vimarsana News

Pfizer Inc.: Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Published: August 31, 2022

Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccines Pfizer-BioNTech Omicron BA.4/BA.5 Bivalent Vaccine combines 15-g of mRNA encoding

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomSylke MaasAlbert BourlaUgur SahinFosun PharmaCenters For DiseaseDrug AdministrationAdvisory Committee On Immunization PracticesExchange CommissionPfizer IncEuropean UnionEuropean Medicines AgencyRoche GroupEmergency Use AuthorizationChief Executive OfficerDisease ControlAdvisory CommitteeImmunization PracticesBiologics ApplicationMarketing Authorization HolderCoronavirus DiseaseVaccine Adverse Event Reporting SystemFact SheetsPrescribing Information